This trial is active, not recruiting.

Conditions peripheral artery disease, severe intermittent claudication
Treatment autologous stem cells (cd34+)
Phase phase 1
Sponsor Losordo, Douglas, M.D.
Start date April 2006
End date December 2012
Trial size 24 participants
Trial identifier NCT00311805, 11931-01, STU00023438/STU00000487


The goal of the study is to determine the safety and possible effectiveness of various doses of autologous (one's own) stem cells, delivered with a needle into the regions of the leg with poor blood flow in patients with blocked leg arteries that results in claudication (pain when walking). Stem cells are primitive cells produced by the bone marrow that can develop into blood cells or other types of cells. In addition to determining whether this new approach is safe, the diagnostic tests may offer preliminary insights into the usefulness of this approach for treating intermittent claudication - the condition where areas in the leg are lacking enough oxygen and blood flow to keep the leg muscle working well, causing pain and cramping upon walking.

This study is a double-blind, randomized study to compare CD34-positive stem cells versus a placebo agent (salt water solution known as normal saline). The patient will have a 3:1 chance of their stem cells versus the placebo. Regardless of a patient receiving placebo or treatment, all patients will undergo all of the pre-treatment phases of this study, which includes the stem cell mobilization and apheresis procedure.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
(Active Comparator)
autologous stem cells (cd34+)
Intramuscular Injections
(Active Comparator)
autologous stem cells (cd34+)
Intramuscular Injections
(Placebo Comparator)
autologous stem cells (cd34+)
Intramuscular Injections

Primary Outcomes

Safety of Intramuscular administration of CD34-positive cells
time frame: All

Secondary Outcomes

Functional improvement
time frame: Week 12, Month 6, Month 12

Eligibility Criteria

Male or female participants at least 21 years old.

Inclusion Criteria: - Males or females equal to or greater than 21 years old - Patients with infra-inguinal atherosclerosis with a stenosis or occlusion of a major vessel in the affected limb(s) of one or more of the following arteries: superficial femoral, popliteal, or one or more infrapopliteal arteries, which is/are non-reconstructable. - Patients with symptoms of Severe Intermittent Claudication in at least 1 lower limb persisting for at least 6 months (Rutherford Class 3). - Patients who have a diagnosis of Peripheral Arterial Disease (PAD) in at least 1 lower limb secondary to atherosclerosis, for at least 6 months. Exclusion Criteria: - Patients who have had successful aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy within 3 month preceding screening. - Patients with iliac disease amenable to revascularization. - Patients judged to be a suitable candidate for surgical or percutaneous revascularization in the limb in which treatment is proposed. - Patients with Critical Limb Ischemia (CLI), Rutherford Symptom Score of 4,5, or 6. - Patients in who arterial insufficiency in the lower extremity is the result of a non-atherosclerotic disorder.

Additional Information

Official title Injection of Autologous CD34-Positive Stem Cells for Neovascularization and Symptom Relief in Patients With Severe Intermittent Claudication
Principal investigator Douglas W. Losordo, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in March 2015.
Information provided to ClinicalTrials.gov by Losordo, Douglas, M.D..